Company Overview and News

 
UPDATE 2-French bank Natixis could bid for payments group Ingenico

2018-10-11 reuters
PARIS (Reuters) - French banking group Natixis (CNAT.PA) is examining a bid for payments company Ingenico (INGC.PA), which confirmed on Thursday it had received several approaches as takeover activity intensifies within the sector.
INGIF ING INGIY

 
UPDATE 1-French bank Natixis examining merging payments business with Ingenico

2018-10-11 reuters
PARIS (Reuters) - French bank Natixis (CNAT.PA) said it was examining a merger of its payments activities with Ingenico (INGC.PA), which has been the subject of bid interest in a sector that has witnessed several takeover deals this year.
INGIF ING INGIY

 
INGENICO GROUP : Communication suite à des publications de presse

2018-10-11 globenewswire
Ingenico Group, (Euronext: FR0000125346 - ING), leader mondial des solutions de paiement intégrées, indique avoir fait l'objet d'approches préliminaires en vue d'une opération stratégique.
INGIF ING INGIY

 
INGENICO GROUP: Communication following press report

2018-10-11 globenewswire
Ingenico Group, (Euronext: FR0000125346 - ING), global leader in seamless payment, indicates that it has received preliminary approaches for a strategic transaction.
INGIF ING INGIY

 
NATIXIS :Communication following press reports

2018-10-11 globenewswire
Natixis has made it clear that it is part of its strategy to further develop and invest in its payment business, including by participating in the consolidation of the sector, and has been reviewing various options to that effect.
INGIF ING INGIY

 
INGENICO GROUP: Third quarter 2018 Revenue - Conference call invitation

2018-10-10 globenewswire
A press release and a presentation will be available on www.ingenico.com prior to the call at (5:40pm).
INGIF ING INGIY

 
INGENICO GROUP : Informations relatives au nombre total de droits de vote et d'actions composant le capital au 30 septembre 2018

2018-10-03 globenewswire
INGENICO GROUP Société Anonyme au capital de 63.144.527 euros Siège social : 28/32 boulevard de Grenelle 75015 Paris RCS Paris : 317 218 758
INGIF ING INGIY

6
Global Payment Partners Ingenico Group to Serve Businesses

2018-09-18 zacks - 1
Global Payments Inc.’s (GPN - Free Report) unit Heartland, dealing in U.S. payments and payroll business, recently collaborated with Ingenico Group to launch an advanced terminal to enrich customer payment experience. The deal would combine Heartland’s technology and software with Ingenico Group’s Desk/3500 terminal, the first of its newly certified Telium Tetra solutions in the United States, which is designed to meet the needs of small to medium Business (SMB) customers.
MGI DFS TXN GPN MDPEB EEFT INGIF MDP ING INGIY

 
Trip.com welcomes Ingenico on board to accelerate international growth

2018-08-22 globenewswire
Ingenico Group (Euronext: FR0000125346 - ING), the global leader in seamless payment, today announced that it will provide payment processing and consulting services to Trip.com, one of the world's leading online travel agencies (OTA) and part of the Ctrip Group - the world's second-largest travel booking company.
CTRP INGIF ING INGIY

 
INGENICO GROUP : Informations relatives au nombre total de droits de vote et d'actions composant le capital au 31 juillet 2018

2018-08-03 globenewswire
INGENICO GROUP Société Anonyme au capital de 63.144.527 euros Siège social : 28/32 boulevard de Grenelle 75015 Paris RCS Paris : 317 218 758
INGIF ING INGIY

 
Ingenico Group SA (INGIY) CEO Philippe Lazare on Q2 2018 Results - Earnings Call Transcript

2018-07-25 seekingalpha
Patrice Le Marre - EVP, Banks & Acquirers Business Unit and Acting Executive VP of Asia Pacific
INGIF ING INGIY

 
INGENICO GROUP : Half-Year Financial report as of June 30, 2018

2018-07-25 globenewswire
Ingenico Group (Euronext: FR0000125346 - ING), the global leader in seamless payment, reported having published and filed today with the Autorité des Marchés Financiers (the AMF), its half-year financial report as of June 30, 2018.
INGIF ING INGIY

 
INGENICO GROUP : Mise à disposition du rapport financier semestriel au 30 juin 2018

2018-07-25 globenewswire
Ingenico Group (Euronext : FR0000125346 - ING), leader mondial des solutions de paiement intégrées, annonce ce jour avoir mis à la disposition du public et avoir déposé auprès de l'Autorité des Marchés Financiers son rapport financier semestriel au 30 juin 2018.
INGIF ING INGIY

 
INGENICO GROUP: Half-year results and signing of the combination agreement of BS PAYONE and Ingenico Retail in Germany, Austria and Switzerland

2018-07-25 globenewswire
Ingenico Group, (Euronext: FR0000125346 - ING), global leader in seamless payment, announced today its results for the six-month period ended as of 30 June 2018.
INGIF ING INGIY

 
INGENICO GROUP : Résultats semestriels et signature de l'accord pour combiner BS PAYONE et Ingenico Retail en Allemagne, Autriche et Suisse

2018-07-25 globenewswire
Ingenico Group, (Euronext: FR0000125346 - ING), leader mondial des solutions de paiement intégrées, annonce aujourd'hui ses états financiers pour le premier semestre 2018 clos le 30 juin.
INGIF ING INGIY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to EPA:ING / INGENICO GROUP on message board site Silicon Investor.

Dividend investing for retirement Dividend investing for retirement Dividend investing for retirement Income Investing Income Investing Income Investing
The coming US dollar crisis The coming US dollar crisis The coming US dollar crisis The Financial Collapse of 2001 Unwinding The Financial Collapse of 2001 Unwinding The Financial Collapse of 2001 Unwinding
Tell a joke - anything goes Tell a joke - anything goes Tell a joke - anything goes TNRG Tianrong Building Materials TNRG Tianrong Building Materials TNRG Tianrong Building Materials
Qualcomm Moderated Thread - please read rules before posting Qualcomm Moderated Thread - please read rules before posting Qualcomm Moderated Thread - please read rules before posting Investing in Exponential Growth Investing in Exponential Growth Investing in Exponential Growth
Sudbury Saturday Night -- Nickel Mining u0026 Nickel Prices Sudbury Saturday Night -- Nickel Mining u0026 Nickel Prices Sudbury Saturday Night -- Nickel Mining u0026 Nickel Prices Mining News of Note Mining News of Note Mining News of Note